{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:52:05Z","timestamp":1778158325121,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":1888,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1097\/jto.0b013e3181f21114","type":"journal-article","created":{"date-parts":[[2010,9,21]],"date-time":"2010-09-21T11:29:35Z","timestamp":1285068575000},"page":"S361-S364","source":"Crossref","is-referenced-by-count":19,"special_numbering":"S4","title":["Targeted Therapy for Advanced Thymic Tumors"],"prefix":"10.1016","volume":"5","author":[{"given":"Arun","family":"Rajan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Giaccone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e3181f21114_bib1","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00432-004-0545-z","article-title":"Tyrosine kinase receptor expression in thymomas","volume":"130","author":"Henley","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f21114_bib2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/path.1514","article-title":"KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas","volume":"202","author":"Pan","year":"2004","journal-title":"J Pathol"},{"key":"10.1097\/JTO.0b013e3181f21114_bib3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.lungcan.2008.03.035","article-title":"Absence of gene mutations in KIT-positive thymic epithelial tumors","volume":"62","author":"Tsuchida","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181f21114_bib4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.lungcan.2008.03.013","article-title":"Mutational status of EGFR and KIT in thymoma and thymic carcinoma","volume":"62","author":"Yoh","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181f21114_bib5","doi-asserted-by":"crossref","first-page":"7068","DOI":"10.1200\/jco.2005.23.16_suppl.7068","article-title":"Phase II study of gefitinib treatment in advanced thymic malignancies","volume":"23","author":"Kurup","year":"2005","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1097\/JTO.0b013e3181f21114_bib6","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/annonc\/mdn388","article-title":"Response of malignant thymoma to erlotinib","volume":"19","author":"Christodoulou","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e3181f21114_bib7","doi-asserted-by":"crossref","first-page":"19087","DOI":"10.1200\/jco.2008.26.15_suppl.19087","article-title":"A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma","volume":"26","author":"Bedano","year":"2008","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1097\/JTO.0b013e3181f21114_bib8","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2741\/2098","article-title":"Cetuximab is an active treatment of metastatic and chemorefractory thymoma","volume":"12","author":"Palmieri","year":"2007","journal-title":"Front Biosci"},{"key":"10.1097\/JTO.0b013e3181f21114_bib9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1470-2045(07)70141-9","article-title":"Response of thymoma to cetuximab","volume":"8","author":"Farina","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1097\/JTO.0b013e3181f21114_bib10","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overexpression of mutated KIT and the response to imatinib","volume":"350","author":"Strobel","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181f21114_bib11","doi-asserted-by":"crossref","first-page":"8116","DOI":"10.1200\/jco.2008.26.15_suppl.8116","article-title":"Imatinib for the treatment of thymic carcinoma","volume":"26","author":"Salter","year":"2008","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1097\/JTO.0b013e3181f21114_bib12","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1097\/JTO.0b013e3181b6be57","article-title":"Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas","volume":"4","author":"Giaccone","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e3181f21114_bib13","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1158\/1078-0432.CCR-07-1786","article-title":"A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors","volume":"14","author":"Steele","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181f21114_bib14","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1200\/jco.2005.23.16_suppl.3147","article-title":"Phase I trials of the oral histone deacetylase (HDAC) inhibitor MGCD0103 given either daily or 3\u00d7 weekly for 14 days every 3 weeks in patients (pts) with advanced solid tumors","volume":"23","author":"Gelmon","year":"2005","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1097\/JTO.0b013e3181f21114_bib15","doi-asserted-by":"crossref","first-page":"7589","DOI":"10.1200\/jco.2009.27.15_suppl.7589","article-title":"Phase II study of the histone deacetylase inhibitor belinostat in thymic malignancies","volume":"27","author":"Giaccone","year":"2009","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1097\/JTO.0b013e3181f21114_bib16","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/JTO.0b013e3181a52e25","article-title":"Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma","volume":"4","author":"Bisagni","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e3181f21114_bib17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12032-008-9100-0","article-title":"Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report","volume":"26","author":"Li","year":"2009","journal-title":"Med Oncol"},{"key":"10.1097\/JTO.0b013e3181f21114_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.25367","article-title":"Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas","author":"Zucali","year":"2010","journal-title":"Cancer"},{"key":"10.1097\/JTO.0b013e3181f21114_bib19","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1158\/1078-0432.CCR-07-1118","article-title":"Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors","volume":"13","author":"Haluska","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3181f21114_bib20","doi-asserted-by":"crossref","first-page":"e17525","DOI":"10.1200\/jco.2010.28.15_suppl.e17525","article-title":"Phase II study of the insulin-like growth factor-1 receptor (IGF-1R) antibody cixutumumab (C) in patients (pts) with thymoma (T) and thymic carcinoma (TC)","volume":"28","author":"Rajan","year":"2010","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1097\/JTO.0b013e3181f21114_bib21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","article-title":"Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial","volume":"22","author":"Loehrer","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181f21114_bib22","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.bjc.6605740","article-title":"Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience","volume":"103","author":"Strobel","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1097\/JTO.0b013e3181f21114_bib23","article-title":"Phase I trial of SU14813 in patients with advanced solid malignancies","author":"Fiedler","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e3181f21114_bib24","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-010-1134-9","article-title":"New predictors of response to neoadjuvant chemotherapy and survival for invasive thymoma: a retrospective analysis","author":"Mineo","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1097\/JTO.0b013e3181f21114_bib25","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejcts.2005.06.034","article-title":"Expression of neurotrophin receptors in surgically resected thymic epithelial tumors","volume":"28","author":"Kim","year":"2005","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1097\/JTO.0b013e3181f21114_bib26","unstructured":"Wakelee HA, Burns M, Gubens M, et al. A phase II study of saracatinib (AZD0530), a SRC inhibitor, administered orally daily to patients (pts) with advanced thymic malignancies (ATM). Abstract submitted for the International Thymic Malignancy Interest Group (ITMIG) Conference, New York, May, 2010."}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415326319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415326319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T10:32:06Z","timestamp":1636540326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415326319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S1556086415326319"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e3181f21114","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}